Adaptimmune is a clinical stage biotechnology company with multiple T-cell therapies in clinical trials or in development. Our expertise and leadership in in immunotherapy is underscored by a large pipeline of therapeutics, all of which have significant potential to improve patient lives and extend life.

We have a strategic alliance with GlaxoSmithKline (GSK) in relation to our NY-ESO T-cell therapy and potentially additional targets.